T A B L E O F C O N T E N

B A C K G R O U N D
Hydrolysed cow's milk formulas, originally developed for infants with cow's milk protein allergy or intolerance, are used as enteral feeding alternatives for preterm infants for whom human milk is unavailable. These formulas contain hydrolysed rather than intact proteins, and may also differ from standard cow's milk formulas in carbohydrate, lipid, and micronutrient type and content (Oldaeus 1997) . Their use as a sole or supplemental enteral feed source for preterm infants has increased since the late-1990s, particularly in high-income countries, because they are perceived as being tolerated better, and less likely to lead to complications, than standard cow's milk formulas (Zuppa 2005) . However, hydrolysed formulas are more expensive than standard formulas, and concern exists that their use in practice is not supported by high quality evidence (Foucard 2005) .
Description of the condition
Human breast milk is recommended as the best form of enteral nutrition for preterm infants (AAP 2012) . Breast milk proteins, carbohydrates, fats, and micronutrients have been optimised by evolution for neonatal digestion and absorption. Breast milk contains many non-nutrient factors including immunoglobulins and lactoferrin that promote intestinal adaptation and maturation, improve enteral feed tolerance, and protect against infection and inflammatory disorders (Agostoni 2010; Arslanoglu 2013) . When sufficient human breast milk is unavailable, cow's milkbased formulas are used for feeding preterm infants, either as the sole enteral diet or as a supplement to human breast milk (Klingenberg 2012) . Feeding preterm infants with standard cow's milk formulas rather than human breast milk is, however, associated with higher rates of feed intolerance and necrotising enterocolitis (Quigley 2014) . Feed intolerance and interruption of enteral feeds is a major contributor to cumulative nutrient deficits and postnatal growth restriction in very preterm infants (Embleton 2001; Cooke 2016) . Slow postnatal growth is associated with neurodevelopmental impairment in later childhood and with poorer cognitive and educational outcomes (Brandt 2003; Embleton 2013a; Leppanen 2014) . Necrotising enterocolitis affects about 5% of very preterm infants. Infants who develop necrotising enterocolitis experience more infections, have lower levels of nutrient intake, grow more slowly, have longer durations of intensive care and hospital stay, and are more likely to die or be disabled than gestation-comparable infants who do not develop necrotising enterocolitis (Morgan 2011; Pike 2012; Yee 2012) .
Description of the intervention
Standard cow's milk formulas can be grouped broadly as 'term' formulas (designed for term infants; nutrient content based on the composition of mature breast milk) and nutrient-enriched 'preterm' formulas (designed for preterm or low birth weight infants; energy-enriched and variably protein-and mineral-enriched) (Fewtrell 1999) . Concern exists that standard cow's milk formulas (either 'term' or 'preterm') are poorly tolerated, especially by very preterm infants, because the immature infant's gastrointestinal tract is less efficient than that of term infants at digesting intact cow's milk proteins and fats (Ewer 1994; Lindberg 1998) .
Hydrolysed formulas
'Hydrolysed' protein formulas, containing protein digested chemically (acid/alkali) or enzymatically (protease) to oligopeptides, are often used for feeding preterm infants, especially infants with feed intolerance or clinical features (such as episodic apnoea, oxygen desaturation or bradycardia) that are attributed to gastro-oesophageal reflux, or following gastrointestinal surgery or necrotising enterocolitis (Zuppa 2005) . Several brands of hydrolysed formulas (both 'term' and 'preterm') are available commercially and these are grouped broadly depending on degree of hydrolysis:
• extensively hydrolysed: residual free amino acids and peptides with molecular weights less than 1.5 kDa to 3.0 kDa;
• partially hydrolysed: residual peptides with molecular weights of 3.0 kDa to 10.0 kDa. This distinction is mainly relevant to the putative hypo-allergenic properties of hydrolysed formulas and there are limited data regarding its functional relevance to preterm infants. Formulas also vary by the predominant protein source (casein versus whey-casein) as well as by carbohydrate (lactose, maltodextrin) and fat (cow, vegetable) type and content (BNFC 2016) .
How the intervention might work
Although developed as hypo-allergenic alternatives to standard cow's milk formulas for infants at risk of cow's milk protein intolerance or allergy, the evidence for this effect in term infants is very weak (Boyle 2016; Osborn 2017) . In preterm infants, hydrolysed formulas are mostly used for their perceived benefits in reducing the risk of feed intolerance and necrotising enterocolitis. When human milk is unavailable, hydrolysed formulas may be used empirically (starter formula) or therapeutically to improve feeding tolerance or reduce gastro-oesophageal reflux. The possible mechanisms for these effects include accelerated gastric emptying and intestinal transit, more efficient enteric peptide digestion, and stimulation of small intestinal enzymatic and motilin activity (Mihatsch 2001b; Zuppa 2005) . If better feed tolerance reduces the time taken to establish full enteral feeding in very preterm infants, this may reduce the adverse infectious or metabolic consequences of prolonged exposure to parenteral nutrition. Several potential adverse effects of hydrolysed formulas are recognised. Osmolality increases when protein is hydrolysed into smaller peptides, and these higher osmolarity fluids delivered to the small intestine may increase the risk of necrotising enterocolitis. Furthermore, if bioactive proteins such as immunoglobulin or lactoferrin are hydrolysed, this may reduce their putative benefits in reducing the risk of infection or necrotising enterocolitis. It is possible that some peptides created by artificial hydrolysis have diminished or harmful functional activities (Embleton 2013b). Concern about micronutrient bioavailability in hydrolysed formulas also exists, particularly whether bone minerals are less well absorbed in the absence of intact casein proteins (Zuppa 2005).
Why it is important to do this review
Given the potential for protein hydrolysate formulas (rather than standard cow's milk formulas) to improve enteral feed tolerance and prevent adverse outcomes in preterm infants, we undertook a systematic review of the randomised trial data to help to inform practice and research.
O B J E C T I V E S
To assess the effect of feeding preterm infants with hydrolysed formula (versus standard cow's milk formulas) on the risk of feed intolerance, necrotising enterocolitis, and other morbidity and mortality in preterm infants.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised or quasi-randomised controlled trials, including cluster-randomised controlled trials.
Types of participants
Preterm (less than 37 weeks' gestation) newborn infants who received cow's milk formula as their sole or supplemental enteral diet.
Types of interventions
Hydrolysed cow's milk formula versus standard (non-hydrolysed) cow's milk formula or another type of hydrolysed cow's milk formula. Formula was to be allocated as at least 20% of intended enteral diet for at least two weeks to allow measurable effects on growth rates and episodes of feed intolerance. Trials should have compared formulas with similar energy and protein levels (i.e. hydrolysed 'preterm' formula versus non-hydrolysed 'preterm' formula, or hydrolysed 'term' formula versus non-hydrolysed 'term' formula). We planned separate comparisons of trials that assessed:
• empirical use of hydrolysed formulas;
• indicated (therapeutic) use of hydrolysed formulas to treat infants with feed intolerance, gastro-oesophageal reflux (and associated apnoea, desaturation or bradycardia), or following gastrointestinal surgery or necrotising enterocolitis (as defined by the primary investigators).
Types of outcome measures Primary outcomes
• Number of infants with at least one episode of feed intolerance that resulted in cessation or reduction in enteral feeding (enteral feeds reduced or ceased for more than four hours), or mean number of episodes of feed intolerance during trial period, or both.
• Infants with at least one episode of necrotising enterocolitis (modified Bell stage 2/3) (Walsh 1986) (unless indicated use following necrotising enterocolitis).
Secondary outcomes
• Time to full enteral feeding independent of parenteral fluids (days).
• Growth: time to regain birth weight, and subsequent rates of weight (grams/kilogram/day), length (millimetre/week), and head growth (millimetre/week) during hospital admission.
• Duration of hospital admission (days).
• Measures of bone mineralisation:
• serum alkaline phosphatase level at 36 to 40 weeks' postmenstrual age or
• bone mineral content assessed post-term by dual energy x-ray absorptiometry (DEXA) or
• clinical or radiological evidence of rickets on longterm follow-up.
• Late-onset invasive infection diagnosed more than 72 hours after birth as determined by culture from a normally sterile site: cerebrospinal fluid, blood, bone or joint, peritoneum, pleural space or central venous line tip; or findings on autopsy examination consistent with invasive microbial infection.
• Mortality: all-cause until 28 days and during hospital admission.
• Neurodevelopmental outcomes assessed by a validated test after 12 months' post-term: neurological evaluations, developmental scores and classifications of disability, including auditory and visual disability.
• Allergy or atopy diagnosed after 12 months' post-term: asthma, eczema, allergic rhinitis or conjunctivitis, food allergy, allergic sensitisation (skin prick, or specific or total immunoglobulin E level) (Boyle 2016 
Searching other resources
We examined reference lists in previous reviews and included studies. We searched the proceedings of the annual meetings of the Pediatric Academic Societies (1993 to 2016), the European Society for Paediatric Research (1995 Research ( to 2016 , the Royal College of Paediatrics and Child Health (2000 to 2017) and the Perinatal Society of Australia and New Zealand (2000 to 2016) . Trials reported only as abstracts were eligible if sufficient information was available from the report, or from contact with the authors, to fulfil the inclusion criteria.
Data collection and analysis
We used the standard methods of Cochrane Neonatal.
Selection of studies
We screened the title and abstract of all studies identified by the search strategy and two review authors independently assessed the full articles for all potentially relevant trials. We excluded those studies that did not meet all the inclusion criteria and we stated the reason for exclusion. We discussed any disagreements until consensus was achieved.
Data extraction and management
Two review authors (DN and WM) extracted data independently using a data collection form to aid extraction of information on design, methodology, participants, interventions, outcomes and treatment effects from each included study. We discussed any disagreements until we reached a consensus. If data from the trial reports were insufficient, we contacted the trialists for further information.
Assessment of risk of bias in included studies
We used the criteria and standard methods of Cochrane Neonatal to assess the methodological quality of any included trials. Two review authors (DN and JKA) assessed risk of bias across key domains (Appendix 2) and resolved disagreements in consultation with a third review author (WM). We requested additional information from the trial authors to clarify methodology and results when necessary. We did not exclude trials on the basis of risk of bias, but we did plan to conduct sensitivity analyses if applicable to explore the consequences of synthesising evidence of variable quality (Higgins 2011).
Measures of treatment effect
We analysed the treatment effects in the individual trials using Review Manager 5 (RevMan 2014) and reported risk ratio (RR) and risk difference (RD) for dichotomous data and mean difference (MD) for continuous data, with respective 95% confidence intervals (CI). We determined the number needed to treat for an additional beneficial outcome (NNTB) or an additional harmful outcome (NNTH) for analyses with a statistically significant difference in the RD.
Unit of analysis issues
The unit of analysis was the participating infant in individually randomised trials and the neonatal unit (or subunit) for clusterrandomised trials. For cluster-randomised trials, we planned to undertake analyses at the level of the participant while accounting for the clustering in the data using the methods recommended in the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011).
Dealing with missing data
Where data were missing, and could not be derived as described, we approached the analysis of missing data as follows.
• We contacted the original study investigators to request the missing data.
• Where possible, we imputed missing standard deviations (SDs) using the coefficient of variation (CV) or calculated from other available statistics including standard errors, CIs, t values and P values.
• If the data were assumed to be missing at random, we analysed the data without imputing any missing values.
• If this could not be assumed, then we planned to impute the missing outcomes with replacement values, assuming all to have a poor outcome. We planned sensitivity analyses to assess any changes in the direction or magnitude of effect resulting from data imputation.
Assessment of heterogeneity
Two review authors assessed clinical heterogeneity, with a metaanalysis conducted only when both authors agreed that study participants, interventions and outcomes were sufficiently similar. We examined the treatment effects of individual trials and heterogeneity between trial results by inspecting the forest plots. We calculated the I² statistic for each analysis to quantify inconsistency across studies and described the percentage of variability in effect estimates that may be due to heterogeneity rather than to sampling error. If we detected moderate or high heterogeneity (I² greater than 50%), we would explore the possible causes (e.g. differences in study design, participants, interventions or completeness of outcome assessments).
Assessment of reporting biases
If more than 10 trials were included in a meta-analysis, we planned to examine a funnel plot for asymmetry.
Data synthesis
We used the fixed-effect model in Review Manager 5 for metaanalyses (as per Cochrane Neonatal recommendations) (RevMan 2014). Where moderate or high heterogeneity existed, we planned to examine the potential causes in subgroup and sensitivity analyses.
Quality of evidence
We assessed the quality of evidence for the main comparisons at the primary outcomes level using the GRADE approach, as outlined in the GRADE handbook (Schünemann 2013; see Appendix 3). Two review authors independently assessed the quality of the evidence for outcomes identified as critical or important for clinical decision-making (feed tolerance and incidence of necrotising enterocolitis). We considered evidence from randomised controlled trials as high quality but downgraded the evidence one level for serious (or two levels for very serious) limitations based upon the following: design (risk of bias), consistency across studies, directness of the evidence, precision of estimates and presence of publication bias. We used the GRADEpro GDT Guideline Development Tool to create a 'Summary of findings' table to report the quality of the evidence.
Subgroup analysis and investigation of heterogeneity
We planned subgroup analyses by:
• gestational age at birth: very preterm (less than 32 weeks) infants versus infants born at 32 weeks or later;
• indication (for therapeutic use): postsurgery versus postnecrotising enterocolitis versus feeding intolerance or gastrooesophageal reflux;
• extent of protein hydrolysis (as defined by manufacturers): extensively versus partially hydrolysed formula.
Sensitivity analysis
We planned sensitivity analyses to determine if the findings were affected by including only studies of adequate methodology (low risk of bias), defined as adequate randomisation and allocation concealment, blinding of intervention and measurement, and less than 10% loss to follow-up.
R E S U L T S Description of studies
Results of the search
From the preliminary search, we identified 1405 records, including three records from other sources. After removing duplicates, we screened 805 separate records against titles and abstracts for relevance. Among these, we excluded 782 articles outright. We shortlisted 21 articles for full-text assessment, with two articles identified as on-going trials (ACTRN12613000481774; Yin 2015). We included 11 trials (Characteristics of included studies table) and excluded seven studies (Characteristics of excluded studies table). See Figure 1 .
One trial is awaiting further data (Del Moral 2017), and two trials await English language translation to allow assessment of eligibility for inclusion (Dobryanskyy 2015; Luo 2016) .
Included studies
We included 11 trials (Huston 1992; Schweizer 1993; Raupp 1995; Pauls 1996 
Participants
In total, 665 infants participated in the included trials. Most participants were clinically stable preterm infants of gestational age less than about 34 weeks or birth weight less than about 1750 g. Few participants were extremely preterm, extremely low birth weight or growth-restricted. Most of the trials specifically excluded infants with congenital anomalies, or gastrointestinal or neurological problems.
Interventions
All the trials assessed the empirical use of protein hydrolysate formulas; none assessed indicated use. Trials varied according to brand of formula studied. All trials except one assessed a "preterm" (nutrient-enriched) hydrolysed formula; Schweizer 1993 assessed a "term" hydrolysed formula. Most trials used a whey-casein-based hydrolysate. Two trials used a predominantly casein-based hydrolysate (Huston 1992; Riezzo 2001) . Most studies assessed a partially hydrolysed formula. Three trials use an extensively hydrolysed formula (Schweizer 1993; Mihatsch 2002; Baldassarre 2017) . One (three-arm) trial randomly allocated infants to receive a partially hydrolysed formula, an extensively hydrolysed formula, or a standard preterm formula (Szajewska 2004) . Control diets were preterm non-hydrolysed formulas in all except Riezzo 2001 where the control diet was a standard term formula. No trials compared hydrolysed cow's milk formula versus another type of hydrolysed cow's milk formula. Trial participants received the intervention or control formulas on commencing enteral feeds either as a sole diet or a supplement when mother's own milk was not available or insufficient. One trial specifically excluded participants post hoc if mother's own milk formed more than 10% of enteral intake (Mihatsch 2002). In general, trial feeds were allocated for several weeks (at least two weeks), or until participating infants reached a specified weight (typically about 1.8 kg).
Outcomes
The outcomes reported most commonly were feed intolerance (reported in various ways but often without accompanying numerical data), growth parameters during the study period or until hospital discharge, and adverse events (including mortality and necrotising enterocolitis). None of the trials reported long-term growth and neurodevelopmental outcomes.
Excluded studies
We excluded seven studies (Rigo 1994; Rigo 1995; Mihatsch 1999; Mihatsch 2001a; Agosti 2003; Corvaglia 2013; Logarajaha 2015) . The reasons for exclusion are described in the Characteristics of excluded studies table.
Risk of bias in included studies
Quality assessments are detailed in the Characteristics of included studies table and summarised in Figure 2 . It is probable that the other trials were not blinded as the reports did not describe any methods that might achieve this.
Incomplete outcome data
Most trials were likely to be at low risk of bias because of incomplete assessment of the trial cohort. In one trial, the investigators recruited 129 infants initially then excluded 42 participants post hoc because they had received more than 10% of their enteral intake as human milk (Mihatsch 2002).
Selective reporting
We were unable to assess reliably whether selective reporting occurred as we did not have protocols or other indicators of prespecified outcomes for any of the trials.
Other potential sources of bias
We did not identify any other potential sources of bias in the reports. 
Effects of interventions
Incidence of necrotising enterocolitis (Outcome 1.2)
Meta-analysis of data from five trials (385 infants) found no difference (typical RR 1.10, 95% CI 0.36 to 3.34; typical RD 0.00, 95% CI -0.03 to 0.04) (I² = 0%) (Analysis 1.2; Figure 3 ). The other trials did not report this outcome, although in most it seems likely that none of the participants developed necrotising enterocolitis. The quality of evidence for the primary outcomes was low because of methodological limitations in the included trials (including uncertainty about allocation concealment and blinding), and imprecision of effect size estimates (Summary of findings for the main comparison).
Time to full enteral feeding (Outcome 1.3)
Most trials did not report time to full enteral feeds (Huston 1992; Raupp 1995; Riezzo 2001; Szajewska 2004; Maggio 2005; Florendo 2009 • Baldassarre 2017: 11 days versus 10 days (SD not reported) 
Time to regain birth weight
One trial reported days to regain birth weight (Schweizer 1993) . This trial found no difference (10 days in the intervention group versus 9 days in the control group; SD not reported).
Weight gain
Three trials reported rates of weight gain over the study period or until hospital discharge (Picaud 2001; Maggio 2005; Florendo 2009 ). Meta-analysis showed that weight gain was slower in the infants fed with hydrolysed formula (MD -3.02 g/kg/day, 95% CI -4.66 to -1.38) (Analysis 1.4; Figure 4 ). 
Length change
Meta-analysis of data from two trials (97 infants) found no difference in length change (MD -0.04 mm/week, 95% CI -1.24 to 1.15) (Analysis 1.5).
Head circumference growth
Meta-analysis of data from two trials (97 infants) found no difference in head circumference growth (MD 0.27 mm/week, 95% CI -0.39 to 0.94) (Analysis 1.6).
Duration of hospital admission
None of the trials reported the duration of hospital admission. 0.17) (Analysis 1.8).
Mortality
None of the trials reported the incidence of mortality.
Neurodevelopmental outcomes
None of the trials reported neurodevelopmental outcomes. One trial assessed allergy or atopy (Szajewska 2004). The trial found no difference in the incidence of "any allergic disease" (atopic dermatitis, gastrointestinal symptoms, wheezing) at 12 months (RR 0.62, 95% CI 0.27 to 1.42; RD -0.13, 95% CI -0.36 to 0.10) (Analysis 1.9).
Subgroup analyses
• Gestational age at birth: very preterm (less than 32 weeks) infants versus infants born at 32 weeks or later: subgroup data not available.
• Indication (for therapeutic use): postsurgery versus postnecrotising enterocolitis versus feeding intolerance or gastrooesophageal reflux: not applicable as all trials assessed empirical use.
• Extent of protein hydrolysis (as defined by manufacturers): data for subgroup analysis sufficient for necrotising enterocolitis (outcome 1.2) only. Three trials used a partially hydrolysed preterm formula (Raupp 1995; Pauls 1996; Florendo 2009) . Two trials used an extensively hydrolysed formula (Mihatsch 1999; Baldassarre 2017) . Meta-analysis found no evidence of a subgroup effect (test for subgroup differences: Chi² = 0.75, df = 1 (P = 0.39), I² = 0%) (Figure 3 ).
Indicated use of protein hydrolysate versus standard formula (Comparison 2)
We found no trials comparing protein hydrolysate versus standard formula.
D I S C U S S I O N
Summary of main results
These data from 11 small randomised controlled trials provided only low quality evidence about how feeding preterm infants (typically stable infants of gestational age less than 34 weeks at birth) with protein hydrolysate rather than standard cow's milk formula affects the risk of feed tolerance, necrotising enterocolitis or other adverse outcomes. Limited data did not indicate any important effects on growth, although a meta-analysis of data from three trials suggested that weight gain was slower in infants fed with protein hydrolysate compared with isocaloric preterm formula. There are currently no data available to assess the effects on growth and neurodevelopmental outcomes beyond the initial hospital admission.
Overall completeness and applicability of evidence
These findings should be interpreted and applied cautiously. The primary outcome, feed intolerance, was reported in various ways, and together with the paucity of numerical data, this precluded meta-analysis. Trials generally reported that feeding with protein hydrolysate did not affect measures such as the prefeed gastric residual volume or the need to cease enteral feeding. Similarly, few trials reported the impact of the intervention on the time to achieve full enteral feeding, and the trials that did report this outcome found no statistically significant or clinically important effects. Although a meta-analysis of five trials (385 participants) found no effect on the risk of necrotising enterocolitis, there were insufficient data to exclude a more modest but still important effect size. The lower bound of the 95% CI was consistent with a 3% absolute risk reduction (i.e. one fewer infant developing necrotising enterocolitis for every 33 infants who received protein hydrolysate formula). Because necrotising enterocolitis is a relatively rare outcome, affecting about 5% of very preterm infants, much larger trials would be needed to provide a more precise estimate of the effect of feeding with protein hydrolysate versus standard formula (Yee 2012). Data on growth parameters are limited, as are data on other adverse outcomes. Furthermore, uncertainty remains about longer-term impact on growth or development. As concerns exist that hydrolysed proteins may be utilised less efficiently than intact proteins by preterm infants, and that concomitant mineral uptake may be lower, trials that assess the effects on both short-and long-term growth and body composition (including bone health) may help to inform policy and practice (Senterre 2016). Another major applicability limitation of this review is that all the included trials were undertaken at healthcare facilities in highincome countries, and none in low-income countries. Therefore, this evidence may be of limited applicability to practices in resource-limited settings where, globally, most preterm and low birth weight infants are cared for (Imdad 2013). All the included trials assessed the effect of empirical (primary) use of protein hydrolysate for feeding preterm infants. We found no trials that assessed the indicated use of protein hydrolysate versus standard formula for preterm infants with feed intolerance, gastrooesophageal reflux (and associated apnoea, desaturation or bradycardia), or following gastrointestinal surgery or necrotising enterocolitis. Although indicated use of protein hydrolysate is common, based on perceptions that formulas with intact proteins may be tolerated poorly by infants with intestinal trauma or compromise, there is no evidence from trials to inform this practice (Lapillonne 2016).
Quality of the evidence
The GRADE assessments indicated that the quality of evidence for the primary outcomes was 'low' because of methodological limitations in the included trials (including uncertainty about allocation concealment and blinding), and imprecision of effect size estimates (Summary of findings for the main comparison). Most of the included trials were funded or supported by the manufacturers of the formulas being assessed but the funders were not involved in trial design or analysis. However, there remains some concern that formula manufacturers may promote study findings of trials of specialist formulas selectively as part of a marketing strategy that subverts UNICEF Baby Friendly Initiative regulations (Cleminson 2015).
Potential biases in the review process
It is possible that our findings were subject to publication and other reporting biases. We attempted to minimise this by screening the reference lists of included trials and related reviews and searching the proceedings of major international perinatal conferences to identify trial reports that were not (or were not yet) published in full form in academic journals. The meta-analyses that we performed did not contain sufficient trials to explore symmetry of funnel plots as a means of identifying possible publication or reporting bias.
A U T H O R S ' C O N C L U S I O N S Implications for practice
This review provides only low quality evidence regarding any benefits or harms of feeding preterm infants with protein hydrolysate versus standard formula. Although there are no trial data to suggest an effect on the risk of feed intolerance or necrotising enterocolitis, the total number of infants studied was small (665 infants) and the data that could be abstracted from published studies for inclusion in meta-analyses were limited.
Implications for research
Further, high-quality randomised controlled trials are needed to assess the benefits and safety of protein hydrolysate versus standard cow's milk formulas for feeding very preterm infants when maternal breast milk is insufficient or not available. Trials could assess primary (empirical) use and secondary (indicated) use in infants with feed intolerance or gastro-oesophageal reflux, or following gastrointestinal surgery or necrotising enterocolitis. Trials should aim to ensure the participation of extremely preterm, extremely low birth weight or growth-restricted infants so that subgroup analyses can be planned for these infants at higher risk of necrotising enterocolitis. Given that protein hydrolysate preterm formulas is more expensive than standard preterm formula, trials could justifiably include a cost-benefit analysis.
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R E F E R E N C E S
References to studies included in this review
C H A R A C T E R I S T I C S O F S T U D I E S Characteristics of included studies [ordered by study ID]
Baldassarre 2017
Methods RCT.
Participants
Preterm infants (28-33 weeks' gestational age; birth weight 700-1750 g and appropriate to gestational age), within 24 hours of first enteral feeding (and whose mother did not plan to exclusively breastfeed)
Interventions Extensively hydrolysed casein infant formula (n = 33). Standard cow's milk-based preterm infant formula (n = 35).
Outcomes
Enteral intake (ml/kg/day) during first 14 days after birth. Interventions Empirical use of partially hydrolysed whey-based formula* (n = 10) Conventional preterm formula* (n = 11).
Maggio 2005 (Continued)
Outcomes Growth rates from inclusion until hospital discharge. Feed intolerance (no infants had enteral feeds interrupted).
Notes
Division of Neonatology, Department of Paediatrics, Catholic University of the Sacred Heart, Rome, Italy Trial date: 1998-2000. * Energy content of both formulas: 75 kCal/100 mL.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence generation (selection bias)
Unclear risk Randomised schedule generated -not specified how.
Allocation concealment (selection bias) Low risk Sealed opaque envelopes.
Blinding of participants and personnel (performance bias) All outcomes
Low risk Study and control formulas identical in colour and smell.
Blinding of outcome assessment (detection bias) All outcomes
Incomplete outcome data (attrition bias) All outcomes
Low risk
Outcomes reported for all participants.
Selective reporting (reporting bias) Unclear risk Protocol not available.
Other bias Unclear risk
Funded by Humana (manufacturer of the trial formula).
Mihatsch 2002
Participants Very low birth weight (< 1500 g) infants.
Interventions Empirical use of extensively hydrolysed (whey-casein) preterm formula* (n = 41) Standard preterm formula* (n = 46). 
Outcomes
Mihatsch 2002 (Continued)
Risk of bias
Bias
Authors' judgement Support for judgement Random sequence generation (selection bias)
Low risk Computer-generated.
Allocation concealment (selection bias) Unclear risk Sealed envelopes -unclear if opaque.
Unclear risk "Double-blind"-same appearance, but investigators acknowledged taste different
Unclear risk "Double-blind."
High risk 129 infants recruited initially, then 42 excluded post hoc because they received > 10% of enteral intake as human milk
Other bias Unclear risk Funder: Milupa GmbH, Germany (manufacturer of the trial formula)
Pauls 1996
Participants
Very low birth weight (< 1500 g) infants.
Interventions Empirical use of partially hydrolysed whey-casein formula* (n = 25) Non-hydrolysed protein formula* (n = 25).
Outcomes
Mean gastric residual volume (% of intake). Time to full enteral feeds. Necrotising enterocolitis.
Pauls 1996 (Continued)
Bias
Authors' judgement Support for judgement
Unclear risk Insufficient information -only abstract available.
Allocation concealment (selection bias) Unclear risk Insufficient information -only abstract available.
High risk Unlikely to be blinded.
Low risk
Other bias Unclear risk Funder: not stated.
Picaud 2001
Participants
Preterm newborns with birth weight < 1500 g and aged < 15 days old when commencing enteral feeds Interventions Empirical use of partially hydrolysed formula* (n = 9). Standard preterm formula* (n = 7). Until 40 weeks' postmenstrual age.
Outcomes
Rate of weight gain during initial hospital admission. Nitrogen balance studies.
Notes
Edouard Herriot Hospital, Claude Bernard University, Lyon, France Trial date: late 1990s. * Energy content of both formulas: 80 kCal/100 mL, but nitrogen content 10% higher in standard preterm formula
Risk of bias
Bias
Authors' judgement Support for judgement
Unclear risk Not stated.
Raupp 1995 (Continued)
High risk Unblinded
Low risk All infants assessed for primary outcomes.
Other bias Unclear risk Funder: Nestle (manufacturer of the trial formula).
Riezzo 2001
Participants
Preterm infants (n = 36).
Interventions
Partially hydrolysed casein preterm formula* (n = 18). Standard (whey-casein) formula* (n = 18).
Outcomes Proportion of infants who had > 1 episode of regurgitation or vomiting per day
Notes Department of Pediatrics, Neonatology Section, University of Bari, Bari, Italy Trial date: 2000. Energy content of hydrolysed formula (80 kCal/100 mL) higher than control standard term formula (68 kCal/100 mL). Because this did not report growth rates (the reason for specifying similar energy levels in comparison formulas), we made a consensus decision to include the trial 
Risk of bias
Szajewska 2004
Participants Preterm infants, bodyweight < 2500 g with ≥ 1 first-degree relative with atopy Interventions Extensively (n = 26) or partially hydrolysed whey-casein preterm formula* (n = 32) Standard preterm formula* (n = 32).
Outcomes Allergic disease in infancy. Feed intolerance.
Notes
Primary aim to assess effects on allergy and atopic disease.
In hospital feed tolerance, growth or adverse outcomes not reported. We contacted corresponding author to seek these data in December 2016 *Energy content of both formulas: 80 kCal/100 mL. 33% "dropout" prior to assessment at 4-5 months' post-term. 
Risk of bias
Characteristics of studies awaiting assessment [ordered by study ID]
Del Moral 2017
Methods RCT (double blind). Randomisation sequence was generated by computer, allocation by sealed envelopes Participants Very low birth weight or very preterm infants (stratified by 2 birth weight categories (500-1000 g and 1001-1500 g) ) who survived > 3 days after birth and for whom breast milk was not available or insufficient for requirements
Interventions Empirical use of 100% whey protein partially hydrolysed preterm formula (n = 62) vs intact preterm formula (n = 73) Breast milk allowed if available and the different formulas were given to supplement when no breast milk available (postrandomisation exclusion if breast milk > 25% of total enteral intake) Outcomes Time to achieve full feeds. Number of days from initiating oral feeds to achieve full feeds Mortality. Necrotising enterocolitis. 
D A T A A N D A N A L Y S E S
